Vnitr Lek 2024, 70(2):E32-E36 | DOI: 10.36290/vnl.2024.030

Focal segmental glomerulosclerosis

Silvie Rajnochová Bloudíčková1, Dana Thomasová2
1 Klinika nefrologie TC IKEM, Praha
2 ÚBLG FN Motol a 2. LF UK, Praha

Focal segmental glomerulosclerosis, FSGS, is a progressive glomerular disease of different ethiology that leads in almost 50 % of patients to end stage renal failure. FSGS is caused by damage of podocytes, histologically characterized by partial scarring of glomeruli, clinically by nephrotic-range proteinuria or nephrotic syndrome and unsatisfactory therapeutic response. Kidney transplantation in FSGS patients is associated with high risk of disease recurrence and worse long-term outcomes. Early treatment is essential for the patient's prognosis, which varies between different forms of FSGS (primary, secondary, genetic).

Keywords: focal segmental glomerulosclerosis, genetics, nephrotic syndrome, recurrence, risk factors, therapy, transplantation.

Accepted: April 10, 2024; Published: April 10, 2024  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Rajnochová Bloudíčková S, Thomasová D. Focal segmental glomerulosclerosis. Vnitr Lek. 2024;70(2):E32-36. doi: 10.36290/vnl.2024.030.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Shabaka A, Ribera AT, Fernández-Juárez G. Focal segmental glomerulosclerosis: State-of-th-art and clinical perspective. Nephron 2020; 144:413-427. doi: 10.1159/000508099 Go to original source... Go to PubMed...
    2. Liu J. and Wang W. Genetic basis of adult-onset nephrotic syndrome and focal segmental glomerulosclerosis. Front Med. 2017 Sep;11(3):333-339. doi: 10.1007/s11684-017-0564-1. Go to original source... Go to PubMed...
    3. Rosenberg AZ, Kopp JB. Focal segmental glomerulosclerosis. Clin J Am Soc Nephrol. 2017 Mar 7;12(3):502-517. doi: 10.2215/CJN.05960616. Go to original source... Go to PubMed...
    4. De Vriese AS, Sethi S, Nath KA, et al. Differentiating Primary, Genetic, and Secondary FSGS in Adults: A Clinicopathologic Approach. J Am Soc Nephrol. 2018 Mar;29(3):759-774. doi: 10.1681/ASN.2017090958 Go to original source... Go to PubMed...
    5. Sethi S, Glassock RJ, Fervenza FC. Focal segmental glomerulosclerosis: towards a better understanding for the practicing nephrologist. Nephrol Dial Transplant 2015 Mar;30(3):375-84. doi: 10.1093/ndt/gfu035 Go to original source... Go to PubMed...
    6. De Vriese AS, Wetzels JF, Glassock R,J et al. Therapeutic trials in adult FSGS: lessons learned and the road forward. Nat Rev Nephrol. 2021 Sep;17(9):619-630. doi: 10.1038/s41581-021-00427-1. Go to original source... Go to PubMed...
    7. Ahn W, Bomback AS. Approach to Diagnosis and Management of Primary Glomerular Diseases Due to Podocytopathies in Adults: Core Curriculum 2020. Am J Kidney Dis. 2020 Jun;75(6):955-964. doi: 10.1053/j.ajkd.2019.12.019. Go to original source... Go to PubMed...
    8. Rovin BH, Adler SG, Barratt J, et al. Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases. Kidney Int. 2021 Oct;100(4):753-779. doi: 10.1016/j.kint.2021.05.015. Go to original source... Go to PubMed...
    9. Osterholt T, Todorova P, Kühne L, et al. Repetitive administration of rituximab can achieve and maintain clinical remission in patients with MCD or FSGS. Sci Rep 2023 Apr 28;13(1):6980. doi: 10.1038/s41598-023-32576-7. Go to original source... Go to PubMed...
    10. Trachtman H. Emerging drugs for treatment of focal segmental glomeruloslerosis. Expert Opin Emerg Drugs. 2020 Sep;25(3):367-375. doi: 10.1080/14728214.2020.1803276. Go to original source... Go to PubMed...
    11. Colucci M, Labbadia R, Vivarelli M, et al. Ofatumumab rescue treatment in post-transplant recurrence of focal segmental glomerulosclerosis. Pediatric Nephrology (2020) 35:341-345. https://doi.org/10.1007/s00467-019-04365-w Go to original source... Go to PubMed...
    12. Miao J, Krisanapan P, Tangpanithandee S, et al. Efficacy of extracorporeal plasma therapy for adult native kidney patients with Primary FSGS: a Systematic review. Ren Fail 2023 Dec;45(1):2176694.doi: 10.1080/0886022X.2023.2176694. Go to original source... Go to PubMed...
    13. Shoji J, Mii A, Terasaki M, Shimizu A. Update on Recurrent Focal Segmental Glomerulosclerosis in Kidney Transplantation. Nephron 2020:144 Suppl 1:65-70.doi: 10.1159/000510748. Go to original source... Go to PubMed...
    14. Bai J, Zhang T, Wang Y, et al. Incidence and risk factors for recurrent focal segmental glomerulosclerosis after kidney transplantation: a meta-analysis. Ren Fail. 2023 Dec;45(1):2201341. doi: 10.1080/0886022X.2023.2201341. Go to original source... Go to PubMed...
    15. Kienzl-Wagner K, Waldegger S, Schneeberger S. Disease Recurrence-The Sword of Damocles in Kidney Transplantation for Primary Focal Segmental Glomerulosclerosis. ont Immunol. 2019 Jul 17:10:1669. doi: 10.3389/fimmu.2019.01669. Go to original source... Go to PubMed...
    16. Garrouste C, Canaud G, Büchler M, et al. Rituximab for Recurrence of Primary Focal Segmental Glomerulosclerosis After Kidney Transplantation: Clinical Outcomes. Transplantation 2017 Mar;101(3):649-656. Go to original source... Go to PubMed...
    17. Wang CS, Liverman RS, Garro R, et al. Ofatumumab for the treatment of childhood nephrotic syndrome. Pediatr Nephrol. 2017 May;32(5):835-841. doi: 10.1007/s00467-017-3621-8. Go to original source... Go to PubMed...
    18. Bernard J, Bruel A, Allain-Launay E, et al. Ofatumumab in post-transplantation recurrence of a pediatric steroid-resistant idiopathic nephrotic syndrome. Pediatr Transplant. 2018 Jun;22(4): e13175. doi: 10.1111/petr.13175. Go to original source... Go to PubMed...
    19. Al Shamsi HR, Shaheen I, Aziz D. Management of recurrent focal segmental glomerulosclerosis (FSGS) post renal transplantation. Transplant Rev (Orlando) 2022 Jan;36(1):100675. doi: 10.1016/j.trre.2021.100675. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.